Brown, Lisle/Cummings, Inc. Biogen Inc. Transaction History
Brown, Lisle/Cummings, Inc.
- $345 Billion
- Q1 2025
A detailed history of Brown, Lisle/Cummings, Inc. transactions in Biogen Inc. stock. As of the latest transaction made, Brown, Lisle/Cummings, Inc. holds 1 shares of BIIB stock, worth $118. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1Holding current value
$118% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding BIIB
# of Institutions
1,016Shares Held
127MCall Options Held
1.77MPut Options Held
2.34M-
Vanguard Group Inc Valley Forge, PA16.7MShares$1.99 Billion0.05% of portfolio
-
Primecap Management CO Pasadena, CA16MShares$1.91 Billion1.94% of portfolio
-
Black Rock Inc. New York, NY14.5MShares$1.73 Billion0.08% of portfolio
-
State Street Corp Boston, MA7.4MShares$880 Million0.05% of portfolio
-
Geode Capital Management, LLC Boston, MA3.7MShares$439 Million0.04% of portfolio
About BIOGEN INC.
- Ticker BIIB
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 144,000,992
- Market Cap $17.1B
- Description
- Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...